Memory CD8+ T Cells and Sepsis Severity: An Observational Study at a Single Center
Official title: Correlation of Memory CD8+ T Cells With Sepsis Severity and Mortality: a Single-center, Unblinded, Prospective, Non-interventional, Observational Study
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT05875740 · Data updated 2026-11-12
This study will observe adults with sepsis to see if certain memory CD8+ T cells correlate with how severe the illness and risk of death are.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | chemotherapy, cyclophosphamide |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | September 6, 2023 |
| Main results expected | October 30, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT05875740 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–60 with sepsis or inflammatory response are eligible, provided there are no exclusion criteria affecting immune indicators or participation.
✕Probably not a fit
Patients with pre-existing immune disorders, recent chemotherapy or radiotherapy, organ transplants, pregnancy, or severe chronic liver/kidney disease may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, non-interventional study conducted at Union Hospital in Wuhan. Researchers will collect data from adult sepsis patients to explore whether central memory CD8+ T cells and related immune markers relate to sepsis severity and mortality. The study uses immune profiling (including T cell subsets) to identify potential immune patterns associated with worse outcomes. No experimental treatments will be given as part of the study, and data will be analyzed to find associations. The findings could help understand immune responses during sepsis and guide future research in prognosis or therapies.
Why it matters
Potential benefit: If successful, the study may help identify immune markers that predict sepsis outcomes and inform future therapeutic or monitoring strategies.
How similar studies have gone: Previous animal and single-cell studies suggest immune cell changes are linked to sepsis, but human data for this specific memory CD8+ T cell focus are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients aged 18-60 years old without restriction of gender, race, religion, creed or nationality; No sedative drugs with elimination half-life were used before inclusion in the study; Patients and/or their family members know and agree to participate in the trial. Exclusion Criteria: History of solid organ or bone marrow transplantation; Diseases that may affect immune-related indicators, such as autoimmune diseases such as rheumatoid arthritis and SLE, or hematological malignancies such as leukemia and lymphoma; Have received radiotherapy or chemotherapy within the past 30 days, or have received immunosuppressive drugs (tripterygium, mycophenolate, cyclophosphamide, FK506, etc); Pregnancy or lactation; Chronic nephrosis; Severe chronic liver disease (child-Pugh: Grade C); alcohol or opioid dependence, mental illness, or severe cognitive impairment; Patients and/or their family members refuse to participate in the trial.
Where it's running
-
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Early detection of sepsis-related blood clotting problems in severe burn patients
This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.
-
Neutrophil EMR3 as a biomarker for sepsis in ICU patients
Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.
-
Thymalfasin added to standard care for adults with sepsis and immune dysfunction
This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.
-
Multicenter group study of sepsis and ARDS in China
This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.